Merus (NASDAQ:MRUS) Hits New 1-Year Low - Time to Sell?

Merus (NASDAQ:MRUS - Get Free Report) reached a new 52-week low during trading on Thursday . The stock traded as low as $33.19 and last traded at $39.56, with a volume of 1057081 shares traded. The stock had previously closed at $34.89.

Wall Street Analysts Forecast Growth

MRUS has been the topic of a number of recent analyst reports. Needham & Company LLC reaffirmed a "buy" rating and set a $83.00 price target on shares of Merus in a report on Wednesday, April 9th. Piper Sandler began coverage on Merus in a research note on Thursday, February 13th. They set an "overweight" rating and a $84.00 target price on the stock. Bank of America decreased their price target on Merus from $73.00 to $70.00 and set a "buy" rating for the company in a research note on Monday, March 10th. William Blair reissued an "outperform" rating on shares of Merus in a report on Friday, February 28th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $85.00 price objective on shares of Merus in a report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $85.31.

Merus Trading Down 1.8 %

The company has a market cap of $2.88 billion, a price-to-earnings ratio of -10.55 and a beta of 1.02. The business has a 50-day moving average price of $43.67 and a 200 day moving average price of $45.20.

Remove Ads

Merus (NASDAQ:MRUS - Get Free Report) last announced its earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.48. The business had revenue of $9.14 million during the quarter, compared to the consensus estimate of $10.57 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. On average, analysts anticipate that Merus will post -3.85 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN lifted its position in shares of Merus by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock valued at $59,000 after acquiring an additional 300 shares in the last quarter. Parkman Healthcare Partners LLC lifted its holdings in shares of Merus by 0.7% in the fourth quarter. Parkman Healthcare Partners LLC now owns 45,680 shares of the biotechnology company's stock valued at $1,921,000 after purchasing an additional 331 shares in the last quarter. Deutsche Bank AG boosted its position in shares of Merus by 0.4% in the fourth quarter. Deutsche Bank AG now owns 113,056 shares of the biotechnology company's stock worth $4,754,000 after buying an additional 416 shares during the period. Geode Capital Management LLC boosted its position in shares of Merus by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 52,636 shares of the biotechnology company's stock worth $2,213,000 after buying an additional 540 shares during the period. Finally, GAMMA Investing LLC grew its holdings in shares of Merus by 2,153.6% during the first quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company's stock valued at $27,000 after buying an additional 603 shares in the last quarter. 96.14% of the stock is owned by hedge funds and other institutional investors.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.